Ophthalmology Innovation Summit

NEW ORLEANS — Glaucoma patients implanted with a bimatoprost ocular insert showed a clinically relevant reduction in IOP over 6 months, according to a study presented here.

NEW ORLEANS — At the Ophthalmology Innovation Summit, James V. Mazzo, chairman and CEO of AcuFocus, discusses the current state of treatment and innovation in improving refractive outcomes for patients, for example, combining anterior segment diagnostics with treatments.

NEW ORLEANS — Roger F. Steinert, MD, was presented with the 2016 OIS Innovator Award here at the Ophthalmology Innovation Summit preceding the American Society of Cataract and Refractive Surgery meeting.

NEW ORLEANS — At the Ophthalmology Innovation Summit, Joe Boorady, president and CEO of TearScience, discusses the introduction of a new HD imager that allows for rapid assessment of meibomian gland dysfunction.

NEW ORLEANS — At the Ophthalmology Innovation Summit, Amar Sawhney, PhD, chairman, CEO and president of Ocular Therapeutix, discusses the company’s therapeutics pipeline and progress in approvals and clinical trials.

NEW ORLEANS — At the Ophthalmology Innovation Summit, Andrew Chang, general manager and vice president U.S. surgical for Bausch + Lomb, discusses the recently announced partnership with IBM, as well as other innovations taking place at the American Society of Cataract and Refractive Surgery meeting.

NEW ORLEANS — At the Ophthalmology Innovation Summit, Tom Mitro, president and COO of Aerie Pharmaceuticals, discusses the current clinical trial status of Roclatan and Rhopressa.

NEW ORLEANS — At the Ophthalmology Innovation Summit, Nick Tarantino, OD, chief of global clinical research and regulatory affairs officer for AcuFocus, gives an update on the launch of the Kamra corneal inlay and the IC-8 small aperture IOL.

NEW ORLEANS — At the Ophthalmology Innovation Summit, John Berdahl, MD, discusses the use of a new orally administered conscious sedation formulation for cataract surgery from Imprimis Pharmaceuticals.

NEW ORLEANS — At the Ophthalmology Innovation Summit, Mark Baum, CEO of Imprimis Pharmaceuticals, discusses two new formulations for use in cataract surgery.